AOD-9604 vs Pramlintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →Pramlintide
Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | Pramlintide |
|---|---|---|
| Dose Range | 300 mcg–500 mcg | 15 mcg–120 mcg |
| Frequency | 1x daily | 3x daily |
| Cycle Length | 12–24 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time. |
| Best For |
What They Have in Common
AOD-9604, Pramlintide are both commonly used for:
Which Has Stronger Evidence?
| Goal | AOD-9604 | Pramlintide |
|---|---|---|
| Fat Loss | medium | medium |
Key Studies
AOD-9604
- AOD-9604 does not influence the WADA hGH isoform immunoassay.
Drug testing and analysis, 2013
- AOD-9604 Metabolic.
Current opinion in investigational drugs (London, England : 2000), 2004
Pramlintide
- Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
Peptides, 2024
- Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.
The Journal of pharmacology and experimental therapeutics, 2024
- Pramlintide for post-bariatric hypoglycaemia.
Diabetes, obesity & metabolism, 2022
Ready to Learn More?
Looking for trusted sources?